tbuckley/cabot-search huggingface dataset:
The novel biomarker HE4 versus CA125 in detecting endometrial cancer: A case control prospective study.
Authors: Francesco Plotti, Marzio Angelo Zullo, Michela Angelucci, Irma Oronzi, Patrizio Damiani, Roberto Montera, Nella Dugo, Federica Guzzo, Maria Antonietta De Oronzo, Roberto Ricciardi, Alessia Aloisi, Entela Hyseni, Daniela Luvero, Rosa Alba Valentina Portuesi, Giuseppe Scaletta, Stella Capriglione, Andrea Miranda, Marta Li Destri, Pierluigi Benedetti Panici, Roberto Angioli
Journal: Journal of Clinical Oncology (2012)

5094 Background: In endometrial cancer, there are no markers routinely used in clinical practice. This study prospectively investigates the sensitivity and specificity of new marker HE4 in detection of endometrial cancer. Methods: Serum samples were prospectively obtained 24 hours before surgery from 25 patients with endometrial cancer and from 25 patients with uterine benign pathology, operated from January 2011 to October 2011 at University Campus Bio-Medico of Rome. Preoperative CA125 levels were evaluated by a one-step “sandwich” radioimmunoassay. HE4 levels were determined using the HE4 enzymatic immune assay. The CA125 normal value is considered less than 35 U/mL. Two HE4 cut-off are considered: less than 70 pmol/L and less than 150 pmol/L. The specificity analysis was performed using the parametric T-Test for comparing the HE4 series and the Mann-Whitney test for the CA125 series. The level of statistical significance is set at p &lt; 0.05. Results: The sensitivity of CA125 in detecting endometrial cancer is 16% whereas the sensitivity of HE4 is 48% and 28 % for 70 pmol/L and 150 pmol/L cut-off respectively. The specificity of HE4 is 100% (positive predictive value = 100%, negative predictive value = 65.79% and 58.14% considering the two HE4 cut-off, respectively), whereas the CA125 specificity is 72 % (positive predictive value = 36.36%, negative predictive value = 46.15%) in detection of endometrial cancer. Conclusions: HE4 has a good sensitivity and a specificity of 100% in detection of endometrial cancer and may be useful for detecting early stage endometrial cancer. In particular the HE4 at cut-off of 70 pmol/L yields the best sensitivity and specificity.
The effect on patients with pulmonary fibrosis (PF) and advanced non small cell lung cancer (NSCLC): A prospective, feasibility study of S-1 and carboplatin.
Authors: Terufumi Kato, Ou Yamaguchi, Masahiro Yoshida, Hiroki Fukushima, Ryo Ogata, Atsuhito Nakazawa, Tsuneyuki Oda, Ryo Okuda, Satoshi Ikeda, Akiyuki Takasa, Noriko Tsuchiya, Takahiro Enomoto, Tomohisa Baba, Hideya Kitamura, Takeshi Shinohara, Ryuichi Nishihira, Shigeru Komatsu, Eri Hagiwara, Takashi Ogura
Journal: Journal of Clinical Oncology (2012)

e19583 Background: PF is commonly concomitant disorder with lung cancer. Because PF sometimes deteriorates and results unfavorable clinical course, patients with PF are excluded from most cancer clinical trials. S-1 is a novel active oral fluoropyrimidine anticancer agent consisting of tegafur, gimeracil and oteracil potassium. Although most anti-cancer agent have pulmonary toxicity, post marketing surveillance reported S-1 has lower pulmonary toxicity incidence. We have conducted feasibility study of S-1 and carboplatin combination for patients with advanced or ineligible for other treatment modality of NSCLC patients. Methods: Patients with histologically or cytologically confirmed NSCLC, clinically diagnosed pulmonary fibrosis, aged 80 years old or younger, performance status 0-2 and chemo naive were eligible for the study. Carboplatin (AUC 5) was administered on day 1 and S-1 (80mg/m 2 /day) on day 1 to 14 for four to six cycles. Endpoints were response rate, common safety profiles and effect to PF. Results: From March 2009 to December 2011, 21 pts (19 males/ 2 females, median age 67 years old, ranged 55 to 77, 10 adenocarcinoma, 10 squamous, 1 adenosquamous, stage IIA: 1, IIIA: 3, IIIB: 9, IV: 4, recurrence: 4) were enrolled. All patients had moderate or severe PF. Treatment delivery; 1 cycle: 3pts, 2: 3pts, 3: 3pts, 4: 10pts, 5; 1pts, 6: 1pts. Partial responses were observed in 7 patients (RR; 33%). The median progression free survival duration was 4.0 months and the median overall survival duration in 10.4 months. During the treatment, 2 patient experienced moderate deterioration of pulmonary fibrosis, 1 experienced infectious pneumonia, all three patients recovered from the event. There was no treatment related death. Besides pulmonary toxicity, most common adverse events were myelotoxicities. Conclusions: This is the first trial of S-1 and carboplatin combination for patients with PF and NSCLC. The study revealed S-1 and carboplatin combination was feasible and active even in patients with PF and NSCLC who are usually excluded from cancer clinical trials.
Significance of EGFR and KRAS gene mutation in small cell lung cancer.
Authors: Koji Kurokawa, Tomoharu Matsui, Hideko Ikeda, Shingo Nishikawa, Takashi Sone, Kazuo Kasahara
Journal: Journal of Clinical Oncology (2013)

e18564 Background: In non-small cell lung cancer, epidermal growth factor receptor (EGFR) and KRAS are known as driver mutations. However the association between these gene alteration and small cell lung cancer (SCLC) has been unclear. The aim of this study is to investigate the gene status of EGFR and Kras in SCLC. Methods: This retrospective study included 66 SCLC patients with available tumor tissue from primary lung tumor or metastatic and clinical data including survival. We evaluated for the presence of EGFR and KRAS mutation those patients using Scorpion-ARMS method. This study was approved by IRB. Results: Sixty-six patients (52 male,14 female median age 68 range 49-89, LD/ED 34/32, PS0-1/2-3 57/9, smoker/never smoker 64/2) were evaluated. Their median overall survival (OS) were 484 days, progression-free survival (PFS) were 217 days. Sixty-six samples were evaluated EGFR mutation test and 61 were evaluated KRAS mutation test by Scorpion-ARMs methods. SCLC patients with EGFR mutation were the only one patients (1.5%,1/66). KRAS mutation were also the only one patients (1.6%,1/61). A 54 years-old nevere-smoker female was already treated with EGFR tyrosine kinase inhibitor for non-small cell lung cancer, the patients with EGFR mutation had a transformation into SCLC. The KRAS mutation patient was combined SCLC with adenocarcinoma. Conclusions: This study suggested that EGFR and KRAS patients associated with SCLC is poor, these driver mutation is unnecessary for common SCLC.
EFFECT OF LOW DOSE COLCHICINE ON THE INCIDENCE OF ATRIAL FIBRILLATION IN OPEN HEART SURGERY PATIENTS: END-AF LOW DOSE TRIAL
Authors: Ramzi A. Tabbalat, Jude Barakat, Yousef Khader, Ayman Hammoudeh, Imad Alhaddad, Hassan AbuKhalaf, Mohammad Obaidat
Journal: Journal of the American College of Cardiology (2020)
Plasma Hepatocyte Growth Factor for Diagnosis and Prognosis in Light Chain and Transthyretin Cardiac Amyloidosis
Authors: Kathleen W. Zhang, Jennifer Miao, Joshua D. Mitchell, Jose Alvarez-Cardona, Kelsey Tomasek, Yan Ru Su, Mary Gordon, R. Frank Cornell, Daniel J. Lenihan
Journal: JACC CardioOncology (2020)

This study determined the diagnostic and prognostic usefulness of hepatocyte growth factor (HGF) in light chain and transthyretin cardiac amyloidosis. Delays in diagnosis of cardiac amyloidosis are common, usually resulting from nonspecific findings on clinical examination and testing. A discriminatory plasma biomarker could result in earlier diagnosis and improve prognosis assessment. A total of 188 patients with cardiac amyloidosis, amyloidosis without cardiac involvement, symptomatic heart failure with left ventricular hypertrophy (LVH), or heart failure with a reduced ejection fraction (HFrEF) were enrolled prospectively. Serum biomarkers were measured at study enrollment, and all patients with amyloidosis were followed for all-cause mortality, cardiac transplantation, or left ventricular assist device implantation. Multinomial logistic regression and Kaplan-Meier survival estimates tested the association of biomarker levels with cardiac amyloidosis and clinical outcomes, respectively. Harrell's C-statistic and the likelihood ratio test compared the prognostic accuracy of plasma biomarkers. HGF was significantly higher in patients with cardiac amyloidosis (p < 0.001). An HGF level of 205 pg/ml discriminated cardiac amyloidosis from LVH and HFrEF with 86% sensitivity, 84% specificity, and an area under the curve of 0.88 (95% confidence interval: 0.83 to 0.94). In patients with amyloidosis, elevated HGF levels were associated with worse event-free survival over a median follow-up of 2.6 years (p < 0.001) with incremental prognostic accuracy over N-terminal pro-B-type natriuretic peptide and troponin T (p < 0.001). HGF discriminates light chain and transthyretin cardiac amyloidosis from patients with symptomatic heart failure with LVH or HFrEF and is associated with worse cardiac outcomes. Confirmation of these findings in a larger, multicenter study that is enrolling suspected cases of cardiac amyloidosis is underway.
Abstract 12993: Low Density Lipoprotein Aggregation is Increased and Predictive of Major Adverse Cardiovascular Events in Patients With Peripheral Artery Disease Undergoing Lower Extremity Revascularization
Authors: Sean P Heffron, Maija K Ruuth, Gustavo Hernandez, Crystalann Rodriguez, Katariina Oorni, Jeffrey S Berger
Journal: Circulation (2019)

Patients with severe PAD undergoing lower extremity revascularization (LER) remain at increased risk for future cardiovascular events beyond the early post-operative period. Identifying those who a...
The continued hunt for the elusive standard short regimen for treatment of multidrug-resistant tuberculosis
Authors: J. Peter Cegielski, Payam Nahid, Giovanni Sotgiu
Journal: European Respiratory Journal (2020)

<b>In low- and middle-income countries, treatment of highly selected MDR-TB patients with a standardised 9–12 month regimen leads to 80% or better successful treatment outcomes</b>http://bit.ly/384SFpY
Mycobacterium tuberculosis bloodstream infection prevalence, diagnosis, and mortality risk in seriously ill adults with HIV: a systematic review and meta-analysis of individual patient data
Authors: David A Barr, Joseph M Lewis, Nicholas Feasey, Charlotte Schutz, Andrew D Kerkhoff, Shevin T Jacob, Ben Andrews, Paul Kelly, Shabir Lakhi, Levy Muchemwa, Helio A Bacha, David J Hadad, Richard Bedell, Monique van Lettow, Rony Zachariah, John A Crump, David Alland, Elizabeth L Corbett, Krishnamoorthy Gopinath, Sarman Singh, Rulan Griesel, Gary Maartens, Marc Mendelson, Amy M Ward, Christopher M Parry, Elizabeth A Talbot, Patricia Munseri, Susan E Dorman, Neil Martinson, Maunank Shah, Kevin Cain, Charles M Heilig, Jay K Varma, Anne von Gottberg, Leonard Sacks, Douglas Wilson, S Bertel Squire, David G Lalloo, Gerry Davies, Graeme Meintjes
Journal: The Lancet Infectious Diseases (2020)

The clinical and epidemiological significance of HIV-associated Mycobacterium tuberculosis bloodstream infection (BSI) is incompletely understood. We hypothesised that M tuberculosis BSI prevalence has been underestimated, that it independently predicts death, and that sputum Xpert MTB/RIF has suboptimal diagnostic yield for M tuberculosis BSI.
Neoadjuvant treatment of primary inoperable or local recurrent thymoma with octreotide LAR to improve tumor resectability.
Authors: Berthold Schalke, Sandra Boy, Hans-Stefan Hofmann, Philipp Stroebel, Joerg Marienhagen, Christoph May, Andrea Stuermer, Alexander Marx
Journal: Journal of Clinical Oncology (2012)

7105 Background: The therapeutic outcome for unresectable, locally advanced, malignant thymoma is poor. Most important factor for long-term survival in thymoma patients is complete resection (R0) of the tumor. The study was performed to evaluate the efficacy of octreotide LAR plus prednisone in patients with primary inoperable or local recurrent thymoma to reduce tumor size. Methods: This was an open label, single-arm study in patients with inoperable or local recurrent thymoma. Patients were considered unlikely to achieve R0 resection at enrollment. Octreotide LAR was administered once every 2 weeks in combination with prednisone. Two stages were planned according to Fleming’s one sample multiple testing procedure for phase II clinical trials. The objective of the study was to show that octreotide LAR is effective in this patient population with respect to tumor shrinkage. Response was defined as decrease in tumor volume of at least 20% at month 3 as compared to baseline. Results: 17 thymoma patients at Masaoka stage III were recruited. Octreotide LAR showed a response in 15 of 17 patients (88.24%) at week 12. Two patients had discontinued the study before week 12 due to unsatisfactory therapeutic effect or adverse events. At Week 12, 5 patients (29.41%) operable for radical resection. 10 patients (58.82%) were not operable for radical resection. 16 of 17 patients (94.12%) experienced adverse events (AEs). The most frequent AEs were gastrointestinal disorders (70.59%), infections and infestations (64.71%), and blood/lymphatic system disorders (41.18%). Conclusions: Octreotide LAR was shown to be effective in patients with inoperable thymoma with respect to tumor shrinkage.Octreotide LAR was generally well tolerated. The reported AEs are in accordance with the known safety profile.
Combined nucleus pulposus augmentation and annulus fibrosus repair prevents acute intervertebral disc degeneration after discectomy
Authors: Stephen R. Sloan, Christoph Wipplinger, Sertaç Kirnaz, Rodrigo Navarro-Ramirez, Franziska Schmidt, Duncan McCloskey, Tania Pannellini, Antonella Schiavinato, Roger Härtl, Lawrence J. Bonassar
Journal: Science Translational Medicine (2020)

Tissue-engineered therapies targeting the nucleus pulposus and annulus fibrosus prevent intervertebral disc degeneration after discectomy in sheep.
Role of adjuvant radiation in patients with squamous cell carcinomas of the oral cavity.
Authors: Steven Brad Maron, Bonnie Gould Rothberg, Michael Otremba, Benjamin Judson, Daniel Morgensztern
Journal: Journal of Clinical Oncology (2013)

6042 Background: Although surgery is the initial treatment of choice for patients with stage III squamous cell carcinoma (SCC) of the oral cavity (OC), the role of adjuvant radiotherapy (RT) remains undefined. We evaluated the differences in outcome according to stage subsets and use of adjuvant RT. Methods: The Surveillance Epidemiology and End Results (SEER) database was queried for patients with SCCOC, treated with surgery (S), RT, or both (SRT); older than 21 years; and diagnosed between 2004 and 2009. Patients with extracapsular lymph node extension or multiple primary cancers were excluded. Overall Survival (OS) rates were estimated by the Kaplan-Meier method and compared using log-rank testing as well as Cox proportional hazards. Results: Among the 1,051 patients meeting eligibility criteria, the most common treatment was SRT (49.1%), followed by S alone (28.9%), and RT alone (22.0%). The 5-year OS ranged from 33.3% in T3N1 to 52.8% in T1N1. Compared to S alone, the addition of RT improved 5-year OS in the entire cohort from 39.5% to 51.1% (HR 0.69, 95% CI 0.54-0.87, p = 0.002). This benefit, however, was significant only for stage T3N0 with a trend towards improvement in the T3N1 group. No significant benefit was observed in T1N1 or T2N1 disease (Table). Conclusions: Stage III SCC of the oral cavity is a heterogeneous disease with significant differences in survival according to its subsets. Adjuvant RT was associated with improved survival for patients with stage T3N0 disease but not T1N1 or T2N1. The benefit of RT in T3N1 cases did not reach statistical significance likely due to the small number of patients. If confirmed in prospective studies, further subdivision of stage III SCC of OC may be necessary, and the indication for RT may be restricted to patients with T3 disease. [Table: see text]
Abstract 12761: Simultaneous Closure of Mitochondrial Connexin43 and Mitochondrial KAtp Channels Increases the Occurrence of Arrhythmias
Authors: Natsuki Morita, Taiki Hasegawa, Yui Takahashi, Ayana Matsumoto, Haruka Sato, Masahito Miura
Journal: Circulation (2018)

Introduction: Connexin43 (Cx43) is a major connexin that forms gap junction channels in the heart and is also present in the inner mitochondrial membrane (mCx43). We have previously reported that t...
THE METHOD OF PREDICTION OF SEVERE CONDUCTION DISTURBANCE AFTER TRANS CATHETER AORTIC VALVE REPLACEMENT ASSESSED BY FOUR-DIMENSION COMPUTED TOMOGRAPHY COLOR MAP IMAGING
Authors: Masaru Kuroda, Ryo Ogawa, Yuya Suzuki, Tsubasa Noda, Tomoo Fujioka, Kazuma Okamoto, Taro Hayashi, Satoshi Tobe
Journal: Journal of the American College of Cardiology (2020)
PROGNOSTIC VALUE OF STROKE VOLUME INDEX IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION AT INTERMEDIATE RISK
Authors: Fabio Dardi, Massimiliano Palazzini, Elisa Zuffa, Daniele Guarino, Alessandro De Lorenzis, Filippo Pasca, Ilenia Magnani, Mariangela Rotunno, Alberto Ballerini, Alessandra Manes, Nazzareno Galié
Journal: Journal of the American College of Cardiology (2020)
LEFT ATRIAL FUNCTION ASSESSED BY SPECKLE TRACKING ECHOCARDIOGRAPHY PREDICTS RECURRENCE OF ATRIAL FIBRILLATION AFTER CATHETER ABLATION: A RACE ECHOCARDIOGRAPHIC SUB-STUDY
Authors: Anne Bjerg Nielsen, Samuel Soerensen, Kristoffer Skaarup, Kasper Djernaes, Raúl S.J. Estépar, Morten Hansen, René Worck, Arne Johannessen, Jim Hansen, Tor Biering-Sorensen
Journal: Journal of the American College of Cardiology (2020)
CLO20-029: The Prognostic and Predictive Significance of Joint İnvestigation of Tumor Marker CA 15-3 and Vitamin D in Breast Cancer Patients
Authors: Jamil A. Aliyev, Elchin Mansurov, Sevinj E. Rahimzade, Azad A. Karimli, Leylakhanum A. Melikova
Journal: Journal of the National Comprehensive Cancer Network (2020)

"CLO20-029: The Prognostic and Predictive Significance of Joint İnvestigation of Tumor Marker CA 15-3 and Vitamin D in Breast Cancer Patients" published on 20 Mar 2020 by National Comprehensive Cancer Network.
ACUTE STRUCTURAL CHANGES IN TRICUSPID ANNULUS FOLLOWING TAVR
Authors: Edith Posada, Alda Bregasi, Xochitl Ortiz, Juan B. Ivey-Miranda, Maria Paredes, Ben A. Lin, Robert McNamara, David Hur, Bernardo Lombo, Antonio Arias, Ian Crandall, Jason Pereira, Lissa Sugeng
Journal: Journal of the American College of Cardiology (2020)
Concommitant boost: An effective regimen in locoregionally advanced head and neck cancers—A phase III randomised trial from a single institute in India
Authors: G. J. Sastri, S. Ghoshal, T. S. Kehwar, S. C. Sharma
Journal: Journal of Clinical Oncology (2006)

5546 Background: The basic objective of this randomized trial was to test the efficacy of concomitant boost against standard fractionation in advanced head and neck cancers. Material and Methods: 285 patients with advanced head and neck cancers were randomized to receive either conventional radiotherapy 66 Gy/33 #/6.5 weeks or concomitant boost to a dose of 67.5 Gy/40 #/5 weeks. Results: The compliance to treatment was equal in both the arms.With a median follow up of 24 months, patients treated with concomitant boost had a significantly better two-year disease free survival and overall survival (p = 0.007 and p = 0.001respectively) than those treated by conventional fractionation. Grade III mucositis was seen in 35% patients in the concomitant boost arm and 19% in the conventional arm. On univariate analysis, the difference in outcome of oropharyngeal lesion p = 0.000, T3&amp;T4 lesions (p = 0.004), Stage IV disease (p = 0.0005) and N+ disease (p = 0.000) were statistically significant in favour of concomitant boost arm. On multivariate analysis base of tongue site was an independent prognostic factor. Conclusions: Concomitant boost is an effective regimen in advanced head and neck cancers. In developing countries where 50–60% patients present at an advanced stage, this seems to be an optimal radiation therapy regimen especially in advanced oropharyngeal cancers. No significant financial relationships to disclose.
A RED HERRING: PATENT FORAMEN OVALE IN RECURRENT VASCULAR THROMBOEMBOLISMS
Authors: Sagar Vadhar, Ghulam Akbar, Kailyn Mann, Tarick Sheikh, Umair Tariq, Bilal Saqi, Paul Secheresiu, Lekha Racharla, Damon McEnroe, Preysi Patel, Emilee Kurtz, Brian Holahan, Amogh Joshi, Tom Quinn, Kourtney Erickson, Chris Lenivy, Rob Decker, Shivtaj Mann, Amy M. Ahnert
Journal: Journal of the American College of Cardiology (2020)
Neogenin neutralization prevents photoreceptor loss in inherited retinal degeneration
Authors: Jason Charish, Alireza P. Shabanzadeh, Danian Chen, Patrick Mehlen, Santhosh Sethuramanujam, Hidekiyo Harada, Vera L. Bonilha, Gautam Awatramani, Rod Bremner, Philippe P. Monnier
Journal: Journal of Clinical Investigation (2020)

Inherited retinal degenerations (IRDs) are characterized by the progressive loss of photoreceptors and represent one of the most prevalent causes of blindness among working-age populations. Cyclic nucleotide dysregulation is a common pathological feature linked to numerous forms of IRD, yet the precise mechanisms through which this contributes to photoreceptor death remain elusive. Here we demonstrate that cAMP induced upregulation of the dependence receptor neogenin in the retina. Neogenin levels were also elevated in both human and murine degenerating photoreceptors. We found that overexpressing neogenin in mouse photoreceptors was sufficient to induce cell death, whereas silencing neogenin in degenerating murine photoreceptors promoted survival, thus identifying a pro-death signal in IRDs. A possible treatment strategy is modeled whereby peptide neutralization of neogenin in Rd1, Rd10, and Rho P23H–knockin mice promotes rod and cone survival and rescues visual function as measured by light-evoked retinal ganglion cell recordings, scotopic/photopic electroretinogram recordings, and visual acuity tests. These results expose neogenin as a critical link between cAMP and photoreceptor death, and identify a druggable target for the treatment of retinal degeneration.